A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia-Reference-Cited by-同舟云学术

A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia

Published:1999-11 Issue:5 Volume:117 Page:1164-1172
ISSN:0016-5085
Container-title:Gastroenterology
language:en
Short-container-title:Gastroenterology

Author:

Shiffman Mitchell L.,Hofmann Charlotte M.,Contos Melissa J.,Luketic Velimir A.,Sanyal Arun J.,Sterling Richard K.,Ferreira-Gonzalez Andrea,Mills A.Scott,Garret Carlton

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference46 articles.

1. Interferon alfa-2b monotherapy versus interferon alfa 2b plus ribavirin as initial treatment for chronic hepatitis C: results of a US multi-center randomized controlled trial;McHutchinson;N Engl J Med,1998

2. Recombinant interferon alfa-2b alone or in combination with ribavirin for retreatment of interferon relapse in chronic hepatitis C;Davis;N Engl J Med,1998

3. Randomized trial of interferon alfa-2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alfa-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C;Poynard;Lancet,1998

4. Randomized, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish study group;Reichard;Lancet,1998

5. Gradual reduction in interferon dose reduces the incidence of relapse in patients with chronic hepatitis C: results of a randomized controlled trial;Shiffman;Hepatology,1996

Cited by 238 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Reprogramming viral immune evasion for a rational design of next-generation vaccines for RNA viruses;Frontiers in Immunology;2023-04-17

2. Regression of liver fibrosis over a 24-week period after completing direct-acting antiviral therapy in patients with chronic hepatitis C receiving care within the national hepatitis C elimination program in Georgia;European Journal of Gastroenterology & Hepatology;2017-11

3. The viral innate immune antagonism and an alternative vaccine design for PRRS virus;Veterinary Microbiology;2017-09

4. Viral hepatitis and hepatocellular carcinoma: etiology and management;Journal of Gastrointestinal Oncology;2017-04

5. Efficacy of daclatasvir/asunaprevir according to resistance-associated variants in chronic hepatitis C with genotype 1;Journal of Gastroenterology;2016-05-28